Insight Molecular Diagnostics Inc. (IMDX)
NASDAQ · Manufacturing · In vitro & in vivo diagnostic substances
$3.93−$0.0205 (−0.52%) on the dayAs of the close; data may be delayed.
IMDX price, last 12 months
Key stats
- Previous close
- $3.95
- Open
- $4.10
- Day range
- $3.76 – $4.10
- 52-week range
- $2.42 – $8.51
- Volume
- 306.6K
- Avg volume (20 days)
- 244K
- Market cap
- $128.3M
Performance
1W−1.8%
1M−8.6%
3M−27.2%
6M−4.4%
YTD−47.6%
1Y+20.0%
vs S&P 500, 1Y+3.2 pts
Technicals and fundamentals
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
- Sector
- Manufacturing
- Industry
- In vitro & in vivo diagnostic substances
- Listed on
- NASDAQ
- Market cap
- $128.3M